Latest ArticlesA method for determining the particle size distribution of lurasidone hydrochloride(1) bulk drug was established and validated. A laser particle size analyzer was used with organic injection mode. By examining the parameters such as dispersant and dosage, refractive index and absorption rate of the sample material, ultrasound time, and stirring cycle speed, the accuracy, precision, stability, and durability of the method were verified. The results showed that the parameters of the established method for determination of particle size distrubition of 1 were as follows: the refractive index of the sample material was 1.65, the absorption index was 0.01, the refractive index of the dispersant was 1.42, the light shielding degree was 12% - 20%, and the stirring cycle speed was 2 500 r/min, the sample measurement time and background time were both 10 s, and the sample was measured for 6 times. This method has high precision, good stability and durability. The RSDs of d(0.5), d(0.1), and d(0.9) of 1 were all less than 3%, which met the specified requirements and could be used for particle size determination of 1 bulk drug.
As the population ages, the need for medications tailored to older adults becomes increasingly critical. Due to pathophysiological changes, comorbidities, and polypharmacy, older adults may respond differently to drugs than younger individuals. This necessitates targeted drug development and adjusted dosages. However, older adults, particularly those over 80 years of age, are often underrepresented in clinical trials. This lack of research data hinders the safe and effective use of medications in this age group. New drug development and clinical research hold immense potential for improving the well-being of older adults. To achieve this, strong collaboration between governments, pharmaceutical companies, and research institutions is essential. In-depth studies on how medications interact with the aging body are crucial. Furthermore, establishing a robust scientific evaluation system, informed by both policy and scientific advancements, is paramount to ensure the safety and efficacy of medications for older adults. This article explores key considerations for new drug development and clinical research specific to this growing demographic, taking into account both domestic and international regulatory developments.
Site-specific integration of large DNA fragments based on non-viral methods are widely used in gene therapy and cell therapy because of their low cost, large capacity, non-immunogenicity, and the ability to avoid genotoxicity and oncogene expression. According to the mechanism, non-viral methods can be classified into three types, DNA damage repair-, recombinase- and transposase-based site-specific integration technologies. All three non-viral DNA targeting methods can be combined with the clustered regularly interspaced short palindromic repeats(CRISPR) and CRISPR associated proteins 9(Cas9) technology to quickly and easily direct exogenous DNA to the target DNA region. In this study, the research progress of the three non-viral-based DNA targeting methods and their applications are summarized to provide new ideas for the development of more efficient cell therapy systems.
Microneedles are a novel transdermal drug delivery method with the advantage of improving drug permeation efficiency and bioavailability. However, microneedle technology faces problems such as insufficient hardness and poor drug delivery accuracy in actual clinical applications. Bionics is a scientific approach that constructs technical systems with specific functions by utilizing the functions and behaviors of biological systems in nature, it can effectively achieve innovative integration between systems, and provide new ideas for solving above problems. At present, bionic microneedles are widely applied in the medical field, such as assisting in wound healing, surgical operations, and physiological/pathological monitoring. This paper summarizes the researches on improving microneedle performance using bionics, and discusses the clinical development prospects of bionic microneedles to provide a new perspective for the future development of microneedle technology.
In situ gel is a novel formulation which is administered in solution and can rapidly occur phase transformation at the site of application to become semi-solid or solid gel. In addition, it can respond to the changes in external factors such as temperature, light, pH value, hydrophily/hydrophobicity, ionic strength. In situ gel has shown unique advantages in a variety of applications, including ophthalmic, nasal, oral, transdermal, injectable and vaginal routes, due to its excellent biocompatibility, bioadhesion ability, sustained- and controlled-release properties. In this paper, the advantages and disadvantages of traditional dosage forms and in situ gel are compared according to the characteristics of various routes of administrations. The research progress of in situ gel in above routes is introduced, and some approval in situ gel products are presented.
Inflammatory bowel disease(IBD) is a chronic intestinal inflammatory disease with an increasing incidence rate year by year, but its etiology is still unclear. And there is a lack of well-targeted and safe therapeutic drugs. In recent years, probiotics have shown large potential as a potential treatment strategy for the prevention and treatment of IBD. This paper elaborates on the mechanism of probiotics in the treatment of IBD, summarizes common probiotic species used in the treatment of IBD, and looks forward to the application of probiotics, aiming to lay a foundation for the research on probiotics in the treatment of IBD.
In order to control the quality of dexmethylphenidate hydrochloride(1), possible impurities were traced and synthesized, including four impurities of 1, namely (±)-threo-2-phenyl-2-(piperidin-2-yl)acetic acid(impurity A), (±)-erythro-methyl-2-phenyl-2-(piperidin-2-yl)acetate(impurity B), (±)-threo-ethyl-2-phenyl-2-(piperidin-2-yl)acetate(impurity E), dimethyl 2,2'-(piperidine-1,2-diyl)bis(2-phenylacetate)(impurity G), and two intermediate impurities, namely (E)-4-methyl-N'-[2-oxo-1-phenyl-2-(piperidin-1-yl)ethylidene]benzenesulfonohydrazide(impurity α)and 2,2'-(hydrazine-1,2-diylidene)bis[2-phenyl-1-(piperidin-1-yl)ethan-1-one](impurity β). The structures of above six impurities were confirmed by 1H NMR, 13C NMR and MS, which could be used as reference substances for the quality control of 1, and provided references for isolation and purification of 1.